ATTITUDES ON WARFARIN PHARMACOGENETIC TESTING IN CHINESE PATIENTS AND PUBLIC

被引:4
|
作者
Chan, Sze Ling [1 ]
Low, Joshua Jun Wen [2 ]
Chia, Kee Seng [1 ,3 ,4 ,5 ,6 ]
Wee, Hwee-Lin [2 ,7 ]
机构
[1] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore
[2] Natl Univ Singapore, Dept Pharm, Singapore 117548, Singapore
[3] Natl Univ Singapore, Ctr Mol Epidemiol, Singapore 117548, Singapore
[4] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[5] Genome Inst Singapore, Singapore, Singapore
[6] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore
[7] Singapore Gen Hosp, Dept Rheumatol & Immunol, Singapore, Singapore
关键词
Warfarin; Pharmacogenetic testing; Attitudes; Asian; ADVERSE DRUG-REACTIONS;
D O I
10.1017/S026646231300069X
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: Genetic factors affecting warfarin maintenance dose have been well established, but patient acceptance is a necessary consideration for the successful clinical implementation of warfarin pharmacogenetic testing (WPGT). In this study, we aimed to determine the attitudes toward WPGT among Singaporean Chinese. Methods: A total of 194 warfarin patients and 187 members of the public completed a structured survey on paper and the Internet, respectively. Attitudes were expressed as willingness to undergo WPGT (single item with 5-point response) and expectations and concerns about WPGT (two multi-item scales). Relationships between attitudes and socio-demographic and clinical variables were explored using Fisher's exact test, Student's t-test, one-way analysis of variance or Pearson's correlation. Results: Majority of respondents were willing to or neutral about undergoing WPGT. Both patients and public had relatively high expectations (mean [SD]: 3.77 [0.63], and 3.97 [0.55], respectively) and moderately high concerns (mean [SD]: 3.30 [0.69] and 3.33 [0.68], respectively) about WPGT. Willingness to undergo WPGT was associated with gender, educational status, length of warfarin treatment, and number of chronic diseases among warfarin patients, and with history of adverse drug reactions and number of chronic diseases among the public. Higher expectation of WPGT was associated with higher willingness (p < .001 in both populations), while higher concern was associated with lower willingness to undergo WPGT among the public (p = .004) but not among patients (p = .072). Conclusion: Patient acceptance is not a major barrier to clinical implementation of WPGT but patient education is necessary and the ethical, social, and legal issues should be addressed.
引用
收藏
页码:113 / 120
页数:8
相关论文
共 50 条
  • [21] Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation
    Xu, Qiang
    Xu, Bin
    Zhang, Yuxiao
    Yang, Jie
    Gao, Lei
    Zhang, Yan
    Wang, Hongjuan
    Lu, Caiyi
    Zhao, Yusheng
    Yin, Tong
    THROMBOSIS AND HAEMOSTASIS, 2012, 108 (06) : 1132 - 1140
  • [22] Clinical utility of pharmacogenetic testing in the treatment of bipolar disorder of Chinese patients
    Xu Huilei
    Chen Siyu
    Xu Jianghua
    Ren Jidong
    Ren Yi
    PHARMACOGENOMICS, 2020, 21 (11) : 761 - 770
  • [23] Measuring knowledge and attitudes towards the utilization of pharmacogenetic testing among physicians
    Muflih, Suhaib
    Bleidt, Barry A.
    Lafferty, Lynn
    Shawaqfeh, Mohammad S.
    Alvarez, Goar
    JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2019, 10 (02) : 227 - 234
  • [24] Using Pharmacogenetic Testing to Tailor Warfarin Therapy: The Singapore Experience and What the Future Holds
    Chang, Grace Shu-wen
    Tan, Doreen Su-Yin
    EUROPEAN CARDIOLOGY REVIEW, 2020, 15
  • [25] Pharmacogenetic dosing of warfarin in the Han-Chinese population: a randomized trial
    Wen, Ming-Shien
    Chang, Kuan-Cheng
    Lee, Tsong-Hai
    Chen, Ying-Fu
    Hung, Kuo-Chun
    Chang, Yeu-Jhy
    Liou, Chia-Wei
    Chen, Jin-Jer
    Chang, Chien-Hung
    Wang, Chao-Yung
    Jeng, Jiann-Shing
    Chuang, Hui-Ping
    Chen, Ying-Ting
    Chen, Chien-Hsiun
    Wu, Jer-Yuarn
    Chen, Yuan-Tsong
    Lee, Ming Ta Michael
    PHARMACOGENOMICS, 2017, 18 (03) : 245 - 253
  • [26] Genetic Testing Before Anticoagulation? A Systematic Review of Pharmacogenetic Dosing of Warfarin
    Kirsten Neudoerffer Kangelaris
    Stephen Bent
    Robert L. Nussbaum
    David A. Garcia
    Jeffrey A. Tice
    Journal of General Internal Medicine, 2009, 24 : 656 - 664
  • [27] Knowledge, attitudes and education of pharmacists regarding pharmacogenetic testing
    Roederer, Mary W.
    Van Riper, Marcia
    Valgus, John
    Knafl, George
    McLeod, Howard
    PERSONALIZED MEDICINE, 2012, 9 (01) : 19 - 27
  • [28] Genetic Testing Before Anticoagulation? A Systematic Review of Pharmacogenetic Dosing of Warfarin
    Kangelaris, Kirsten Neudoerffer
    Bent, Stephen
    Nussbaum, Robert L.
    Garcia, David A.
    Tice, Jeffrey A.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2009, 24 (05) : 656 - 664
  • [29] Survey of genetic counselors and clinical geneticists' use and attitudes toward pharmacogenetic testing
    Haga, S. B.
    O'Daniel, J. M.
    Tindall, G. M.
    Mills, R.
    Lipkus, I. M.
    Agans, R.
    CLINICAL GENETICS, 2012, 82 (02) : 115 - 120
  • [30] Preliminary outcomes of preemptive warfarin pharmacogenetic testing at a large rural healthcare center
    Leary, Emili
    Brilliant, Murray
    Peissig, Peggy
    Griesbach, Sara
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (06) : 387 - 397